Literature DB >> 17516879

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.

Nathan P Wiederhold1, James S Lewis.   

Abstract

Micafungin is a relatively broad-spectrum antifungal agent available for clinical use in the US and Japan. By inhibiting the production of beta-1,3-glucan, an essential fungal cell wall component, micafungin has reduced toxicity to mammalian cells while maintaining potent antifungal activity against many pathogenic fungi including polyene- and azole-resistant isolates. Indeed, micafungin has been shown to be efficacious in the treatment of infections caused by Candida and Aspergillus species in clinical trials without the associated toxicities of amphotericin B formulations and drug interactions that occur with the azoles. In this review, the pharmacology, spectrum of activity, clinical efficacy and safety profile of micafungin are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516879     DOI: 10.1517/14656566.8.8.1155

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

1.  Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.

Authors:  Annie Lee; Brendan Prideaux; Matthew Zimmerman; Claire Carter; Stephen Barat; David Angulo; Véronique Dartois; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

3.  Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.

Authors:  Souzan B Yanni; P Brian Smith; Daniel K Benjamin; Patrick F Augustijns; Dhiren R Thakker; Pieter P Annaert
Journal:  Biopharm Drug Dispos       Date:  2011-03-30       Impact factor: 1.627

Review 4.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Screening for antifungal peptides and their modes of action in Aspergillus nidulans.

Authors:  Daniel Mania; Kai Hilpert; Serge Ruden; Reinhard Fischer; Norio Takeshita
Journal:  Appl Environ Microbiol       Date:  2010-09-10       Impact factor: 4.792

6.  In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.

Authors:  Souzan B Yanni; Patrick F Augustijns; Daniel K Benjamin; Kim L R Brouwer; Dhiren R Thakker; Pieter P Annaert
Journal:  Drug Metab Dispos       Date:  2010-07-06       Impact factor: 3.922

7.  Development and validation of an in vivo Candida albicans biofilm denture model.

Authors:  Jeniel E Nett; Karen Marchillo; Carol A Spiegel; David R Andes
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

8.  Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Authors:  Maiken Cavling Arendrup; David S Perlin; Rasmus Hare Jensen; Susan Julie Howard; Joanne Goodwin; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 9.  Current perspectives on echinocandin class drugs.

Authors:  David S Perlin
Journal:  Future Microbiol       Date:  2011-04       Impact factor: 3.165

10.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.